Recently, there was a post on the Internet about the recruitment of volunteers to strengthen the vaccination of Dongfang Hospital Affiliated to Tongji University (hereinafter referred to as: Shanghai Dongfang Hospital), recruiting elderly people aged 60-80 who have been infected with the new crown and have been vaccinated, and the subsidy amount Up to 8,000 yuan, distributed in 4 installments.
On July 27, a reporter from China Business News called Shanghai Dongfang Hospital to learn about the situation. A relevant person in charge of the consultation of the vaccine trial project confirmed that this is a clinical trial conducted by the hospital, and it needs to meet several requirements: first, age, which needs to be born before July 1962; second, it needs to have a history of new crown infection , the time of discharge from the hospital should not be less than 7 days; the third is that two or three doses of inactivated vaccine need to be vaccinated, and the last dose of the vaccine needs to be more than 6 months old. In addition, it is also necessary to evaluate the underlying diseases of the elderly, such as hypertension, diabetes, coronary heart disease, etc., as well as allergies.
“People who meet the above conditions will be enrolled in the group after passing the screening. The test group was boosted with the mRNA vaccine of Sri Lanka, and the control group was boosted with a shot of inactivated vaccine, followed by a 3-month follow-up.” The above-mentioned personnel told Yicai.com.
In addition, according to reports, 8,000 yuan is a pre-tax subsidy, which will be distributed in four installments. After the booster vaccination is completed, 2,000 yuan will be distributed, and the remaining part will be distributed successively after blood draws during the 3-month follow-up. Relevant consultants told reporters: “It’s not the end of the vaccine, but it is necessary to ensure that you have been to the hospital about 6 times, and you must arrive at the hospital on time during the follow-up on the 7th, 14th, 28th and 60th days after vaccination. The total amount of blood drawn is 350-400 ml.”
In response to the question of what to do if there is a risk in the clinical trial, the above-mentioned personnel told the first financial reporter that the participants in the trial need to sign in the hospital An informed consent form, at which time the doctor will inform you about the associated risks and how to manage the adverse event.
The hospital did not disclose how many subjects were recruited for the entire clinical trial, but said the clinical trial has been halfway through since it opened in June and is still recruiting subjects.
The first financial reporter learned from the enterprise that the above-mentioned clinical trial was initiated by the researchers of Shanghai Dongfang Hospital, but the hospital did not disclose the specific responsible platform to the first financial reporter, and said that the informed consent will be included. be informed.
About who will pay the 8,000 yuan subsidy, the hospital told Yicai.com that it will be distributed to the trial participants after the hospital has gone through the process, and it may take a while. In addition, according to the first financial reporter’s understanding from relevant persons in the enterprise, the compensation for the inoculated persons shall be borne by the enterprise.
Public information shows that Li Hangwen, founder, chairman and CEO of Sri Lanka Microbiology, is still a researcher of the translational medicine platform of Oriental Hospital. As early as January 2020, Dongfang Hospital released information that it cooperated with Siwei to develop mRNA vaccines.
In addition to Dongfang Hospital, the mRNA vaccine of Sri Lanka is also undergoing clinical trials in Zhongshan Hospital Affiliated to Fudan University, Xuhui District Central Hospital, etc., all of which are clinical trials initiated by researchers. Last month, Zhongshan Hospital released information that the hospital was recruiting subjects for a Phase I clinical exploratory study of Sri Lanka’s mRNA vaccine, requiring those who have not been infected with the new crown, who are under the age of 70, and who have received two injections. Personnel with inactivated COVID-19 vaccine.
The clinical trials published by Zhongshan Hospital were divided into three groups, 1 dose of inactivated vaccine booster group, 1 dose of mRNA 25μg (microgram) booster group, and 1 dose of mRNA 45μg booster group, with 20 cases in each group , subjects were randomized into the group.
As of now, China has not approved any new crown mRNA vaccines for the market, including Si Microorganism, CanSino, CSPC, Watson Bio, etc., are all developing mRNA vaccines.